JP2005525389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525389A5 JP2005525389A5 JP2003579729A JP2003579729A JP2005525389A5 JP 2005525389 A5 JP2005525389 A5 JP 2005525389A5 JP 2003579729 A JP2003579729 A JP 2003579729A JP 2003579729 A JP2003579729 A JP 2003579729A JP 2005525389 A5 JP2005525389 A5 JP 2005525389A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- compound
- aryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 238000009472 formulation Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 10
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000003107 substituted aryl group Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 8
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000005592 polycycloalkyl group Polymers 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- -1 hydroxy, amino Chemical group 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 5
- 101100440696 Caenorhabditis elegans cor-1 gene Proteins 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 101710183280 Topoisomerase Proteins 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- DNRUCKAJUUGDEU-UHFFFAOYSA-N CC(C1)C(Cl)=CC=C1C(Nc1ccc2[nH]c(-c(cc3)ccc3NC(c3cc(Cl)cc(C)c3)=O)nc2c1)=O Chemical compound CC(C1)C(Cl)=CC=C1C(Nc1ccc2[nH]c(-c(cc3)ccc3NC(c3cc(Cl)cc(C)c3)=O)nc2c1)=O DNRUCKAJUUGDEU-UHFFFAOYSA-N 0.000 description 1
- CFMMHANNRNZQGA-UHFFFAOYSA-N CC(Nc(cc1)ccc1-c1nc(cc(cc2)NC(c3ccccc3)=O)c2[n]1Cc1ccccc1)=O Chemical compound CC(Nc(cc1)ccc1-c1nc(cc(cc2)NC(c3ccccc3)=O)c2[n]1Cc1ccccc1)=O CFMMHANNRNZQGA-UHFFFAOYSA-N 0.000 description 1
- KMMWWUCZQHTTOO-UHFFFAOYSA-N Cc1c(C2CCC2)c(Cl)cc(C(Nc(cc2)ccc2-c2nc3cc(NC(c4cnccc4)=O)ccc3[nH]2)=O)c1 Chemical compound Cc1c(C2CCC2)c(Cl)cc(C(Nc(cc2)ccc2-c2nc3cc(NC(c4cnccc4)=O)ccc3[nH]2)=O)c1 KMMWWUCZQHTTOO-UHFFFAOYSA-N 0.000 description 1
- KLTAJSTXVWJRTK-UHFFFAOYSA-N Cc1cc(Cl)cc(C(NC2C=CC(c3nc4cc(NC(c(cc5OC)cc(OC)c5OC)=O)ccc4[nH]3)=CC2)=O)c1 Chemical compound Cc1cc(Cl)cc(C(NC2C=CC(c3nc4cc(NC(c(cc5OC)cc(OC)c5OC)=O)ccc4[nH]3)=CC2)=O)c1 KLTAJSTXVWJRTK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36768602P | 2002-03-25 | 2002-03-25 | |
| PCT/US2003/006981 WO2003082186A2 (en) | 2002-03-25 | 2003-03-06 | Use of benzimidazole analogs in the treatment of cell proliferation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525389A JP2005525389A (ja) | 2005-08-25 |
| JP2005525389A5 true JP2005525389A5 (enExample) | 2006-04-20 |
Family
ID=28675384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003579729A Pending JP2005525389A (ja) | 2002-03-25 | 2003-03-06 | 細胞増殖の治療におけるベンズイミダゾール類似体の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050197375A1 (enExample) |
| EP (1) | EP1494668A4 (enExample) |
| JP (1) | JP2005525389A (enExample) |
| AU (1) | AU2003213768A1 (enExample) |
| CA (1) | CA2479453A1 (enExample) |
| PE (1) | PE20040165A1 (enExample) |
| TW (1) | TW200304820A (enExample) |
| UY (1) | UY27732A1 (enExample) |
| WO (1) | WO2003082186A2 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| CA2441177A1 (en) * | 2001-03-12 | 2002-09-19 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
| EP1496905B1 (en) * | 2002-04-22 | 2008-08-13 | Johns Hopkins University School of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
| TWI276631B (en) * | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| CA2533990A1 (en) * | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| WO2006022442A1 (ja) * | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| AU2005301962B2 (en) | 2004-11-03 | 2011-10-20 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| CA2599989A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| WO2006124780A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
| US20070037865A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| ATE533485T1 (de) † | 2005-10-31 | 2011-12-15 | Merck Sharp & Dohme | Cetp-inhibitoren |
| EP2395002B1 (en) | 2005-11-08 | 2014-06-18 | Vertex Pharmaceuticals Inc. | Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters. |
| AU2012244242B2 (en) * | 2005-12-28 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CN101395147B (zh) * | 2005-12-28 | 2013-05-29 | 弗特克斯药品有限公司 | 作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物 |
| AR063311A1 (es) * | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| EP2121626A1 (en) * | 2006-12-15 | 2009-11-25 | Pfizer Products Inc. | Benzimidazole derivatives |
| NZ581259A (en) | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| GEP20125702B (en) | 2007-06-29 | 2012-12-10 | Pfizer | Benzimidazole derivatives |
| CA2704336A1 (en) * | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
| BRPI0820377A2 (pt) * | 2007-11-08 | 2015-05-19 | Sirtris Pharmaceutical Inc | Tiazolopiridinas solubilizadas |
| UA102534C2 (xx) | 2007-12-07 | 2013-07-25 | Вертекс Фармасьютикалз Инкорпорейтед | ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ) |
| LT2639223T (lt) | 2007-12-07 | 2017-06-26 | Vertex Pharmaceuticals Incorporated | Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas |
| NZ602030A (en) | 2008-02-28 | 2014-02-28 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| WO2009112445A1 (en) * | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| MX2011006555A (es) | 2008-12-19 | 2011-08-03 | Sirtris Pharmaceuticals Inc | Compuestos de tiazolopiridina moduladores de sirtuina. |
| EP2367823A1 (en) | 2008-12-23 | 2011-09-28 | Abbott Laboratories | Anti-viral compounds |
| MX2011006332A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| SG175144A1 (en) * | 2009-04-15 | 2011-11-28 | Abbott Lab | Anti-viral compounds |
| PE20110679A1 (es) * | 2009-06-11 | 2011-10-20 | Abbvie Bahamas Ltd | Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| CN102917692A (zh) | 2010-04-07 | 2013-02-06 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法 |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8912202B2 (en) * | 2011-08-08 | 2014-12-16 | Merck Patent Gmbh | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9649313B2 (en) * | 2012-11-26 | 2017-05-16 | The University Of North Carolina At Chapel Hill | Use of ITK inhibitors for the treatment of cancer |
| GB201302927D0 (en) * | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| BR112016010403A2 (pt) | 2013-11-12 | 2017-08-08 | Vertex Pharma | Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US10005792B2 (en) | 2014-09-03 | 2018-06-26 | Ctxt Pty. Ltd. | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors |
| WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| US10302602B2 (en) | 2014-11-18 | 2019-05-28 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
| WO2017039318A1 (en) * | 2015-09-01 | 2017-03-09 | Kainos Medicine, Inc. | Benzimidazole derivatives for dna methylation inhibitors |
| GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604031D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604030D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| WO2019018562A1 (en) | 2017-07-19 | 2019-01-24 | Ideaya Biosciences, Inc. | AMIDO COMPOUND AS MODULATORS OF AHR |
| US20220340875A1 (en) * | 2018-07-19 | 2022-10-27 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using amido compounds |
| JP7611832B2 (ja) * | 2018-09-18 | 2025-01-10 | ターンズ・インコーポレイテッド | 特定の白血病を治療するための化合物 |
| EP4265247A1 (en) * | 2022-04-22 | 2023-10-25 | Université Paris Cité | Compounds inducing production of proteins by immune cells |
| CN118908896A (zh) * | 2024-09-02 | 2024-11-08 | 广东海洋大学 | 4-（1H-苯并[d]咪唑-2-基）-N，N-双（2-氯乙基）苯胺衍生物及其制备方法与应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3224512A1 (de) * | 1982-07-01 | 1984-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| US4510158A (en) * | 1984-03-05 | 1985-04-09 | Sterling Drug Inc. | 2-Phenylindole derivatives, their use as complement inhibitors |
| US5206257A (en) * | 1987-03-05 | 1993-04-27 | May & Baker Limited | Pesticidal method using 2-phenylimidazole derivatives |
| JP2630432B2 (ja) * | 1987-08-24 | 1997-07-16 | コニカ株式会社 | 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料 |
| FR2658511B1 (fr) * | 1990-02-16 | 1992-06-19 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| US5646281A (en) * | 1990-12-28 | 1997-07-08 | Neurogen Corporation | Certain 4-piperidino- and piperazinomethyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands |
| US5322847A (en) * | 1992-11-05 | 1994-06-21 | Pfizer Inc. | Azabenzimidazoles in the treatment of asthma, arthritis and related diseases |
| US5643893A (en) * | 1994-06-22 | 1997-07-01 | Macronex, Inc. | N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines |
| US5821258A (en) * | 1994-12-27 | 1998-10-13 | Mitsui Chemicals, Inc. | Phenylbenzimidazole derivatives |
| JP3223090B2 (ja) * | 1994-12-27 | 2001-10-29 | 三井化学株式会社 | フェニルベンズイミダゾール誘導体 |
| DE19503160A1 (de) * | 1995-02-01 | 1996-08-08 | Bayer Ag | Verwendung von Phenylcyclohexylcarbonsäureamiden |
| AU714873B2 (en) * | 1995-08-02 | 2000-01-13 | Newcastle University Ventures Limited | Benzimidazole compounds |
| US6387938B1 (en) * | 1996-07-05 | 2002-05-14 | Mochida Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| US6153631A (en) * | 1996-10-23 | 2000-11-28 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| CA2232467A1 (en) * | 1997-03-20 | 1998-09-20 | Richard A. Glennon | Imidazoles with serotonin receptor binding activity |
| SK285357B6 (sk) * | 1997-09-26 | 2006-11-03 | Zentaris Gmbh | Zlúčeniny na báze azabenzimidazolu modulujúce funkciu serínovej/treonínovej proteínkinázy |
| US6100282A (en) * | 1998-01-02 | 2000-08-08 | Hoffman-La Roche Inc. | Thiazole derivatives |
| US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| US6303645B1 (en) * | 1998-05-22 | 2001-10-16 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| US6369091B1 (en) * | 1998-05-22 | 2002-04-09 | Avanir Pharmaceuticals | Benzimidazole analogs as down-regulators of IgE |
| IL139826A0 (en) * | 1998-05-22 | 2002-02-10 | Avanir Pharmaceuticals | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE |
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| EA200100255A1 (ru) * | 1998-08-20 | 2002-02-28 | Агурон Фармасьютикалз, Инк. | НЕПЕПТИДНЫЕ СРЕДСТВА GnRH, СПОСОБЫ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ИХ ПОЛУЧЕНИЯ |
| JP2000095767A (ja) * | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | 性腺刺激ホルモン放出ホルモン拮抗剤 |
| ATE284392T1 (de) * | 1998-11-03 | 2004-12-15 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| EP1131301B1 (de) * | 1998-11-17 | 2005-08-24 | Abbott GmbH & Co. KG | 2-phenylbenzimidazole und 2-phenylindole, deren herstellung und anwendung |
| US6759425B2 (en) * | 1999-10-21 | 2004-07-06 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| CA2441177A1 (en) * | 2001-03-12 | 2002-09-19 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
| JP4658473B2 (ja) * | 2001-07-27 | 2011-03-23 | キュリス，インコーポレイテッド | ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用 |
| TWI276631B (en) * | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| WO2004024655A2 (en) * | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
| MXJL05000041A (es) * | 2003-04-10 | 2005-12-22 | Avanir Pharmaceuticals | Compuestos de imidazol para el tratamiento de padecimientos alergicos e hiperproliferativos. |
| CA2533990A1 (en) * | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
-
2003
- 2003-02-26 TW TW092104005A patent/TW200304820A/zh unknown
- 2003-03-06 EP EP03711459A patent/EP1494668A4/en not_active Withdrawn
- 2003-03-06 JP JP2003579729A patent/JP2005525389A/ja active Pending
- 2003-03-06 WO PCT/US2003/006981 patent/WO2003082186A2/en not_active Ceased
- 2003-03-06 AU AU2003213768A patent/AU2003213768A1/en not_active Abandoned
- 2003-03-06 US US10/508,968 patent/US20050197375A1/en not_active Abandoned
- 2003-03-06 CA CA002479453A patent/CA2479453A1/en not_active Abandoned
- 2003-03-25 PE PE2003000304A patent/PE20040165A1/es not_active Application Discontinuation
- 2003-03-25 UY UY27732A patent/UY27732A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525389A5 (enExample) | ||
| EP1829858A3 (en) | Dibenzylamine compounds and pharmaceutical use thereof | |
| JP2006506443A5 (enExample) | ||
| ATE448226T1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| JP2005518382A5 (enExample) | ||
| WO2002040486A3 (en) | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | |
| JP2005535586A5 (enExample) | ||
| KR930702292A (ko) | 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체 | |
| CA2430273A1 (en) | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them | |
| JP2001525411A5 (enExample) | ||
| WO1999028304A3 (en) | Pdgf receptor kinase inhibitory compounds, their preparation and compositions | |
| RU2000119731A (ru) | Новые тетрациклические аналоги камптотецинов, способы их получения, их применение в качестве лекарств и фармацевтические композиции, их содержащие | |
| JP2005531488A5 (enExample) | ||
| JP2008505157A5 (enExample) | ||
| AU2003220480A1 (en) | Bicyclo 4.4.0 antiviral derivatives | |
| CA2389545A1 (en) | Chemokine receptor binding heterocyclic compounds | |
| WO2010027424A2 (en) | 9-substituted phenanthrene based tylophorine derivatives | |
| RU92016592A (ru) | Вич ингибирующие бензолацетамидные производные | |
| CA2302943A1 (en) | Phthalazine compounds and therapeutic agents for erectile dysfunction | |
| CA2360754A1 (en) | Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors | |
| AU581324B2 (en) | Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones | |
| RU94012934A (ru) | Производные 5-ациламино-1,2,4-тиадиазолов, способ их получения и содержащие их фармацевтические композиции | |
| JP2005511535A5 (enExample) | ||
| CA2485201A1 (en) | Camptothecins with a modified lactone ring | |
| JP2005510468A5 (enExample) |